`Mylan Exhibit 1029
`
`Mylan (IPR2020-00040) Ex. 1029 p. 001
`
`Mylan (IPR2020-00040) Ex. 1029 p. 001
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner,
`
`v.
`
`MERCK SHARP & DOHME CORP.,
`Patent Owner.
`__________________
`
`Case No. IPR2020-00040
`U.S. Patent No. 7,326,708
`__________________
`
`SECOND DECLARATION OF ADAM J. MATZGER
`
`
`1
`
`
`
`
`
`
`
`
`
`Merck Exhibit 2269, Page 1
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040
`
`Mylan (IPR2020-00040) Ex. 1029 p. 002
`
`
`
`
`
`
`
`I, Adam J. Matzger, declare as follows:
`
`1.
`
`I have been informed by counsel for Patent Owner Merck that
`
`Petitioner Mylan has made a number of objections to my lab notebooks and the
`
`data I generated (EX2228, EX2229, and EX2231), which as I described in my
`
`Declaration (EX2103) demonstrate the existence of non-1:1 sitagliptin phosphate
`
`salts. I have therefore been asked by counsel to provide certain additional
`
`information about those experiments and the data I submitted as a part of my
`
`Declaration.
`
`2.
`
`EX2228 is a true and accurate copy of one of my lab notebooks. I
`
`personally performed the experiments described in EX2228, and I
`
`contemporaneously recorded them in that lab notebook as I performed the
`
`experiments.
`
`3.
`
`EX2229 is a true and accurate copy of another one of my lab
`
`notebooks. I personally performed the experiments described in EX2229, and I
`
`contemporaneously recorded them in that lab notebook as I performed the
`
`experiments.
`
`4.
`
`EX2231 is a true, accurate, and complete collection of the data
`
`generated in connection with my work on this case. It is a ZIP archive containing
`
`various electronic data files, which I have organized by the type of experiment into
`
`top-level folders: Elemental Analysis, Optical Microscopy, PXRD, Raman, Single
`
`
`
`2
`
`Merck Exhibit 2269, Page 2
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040
`
`Mylan (IPR2020-00040) Ex. 1029 p. 003
`
`
`
`
`
`Crystal, and TGA. Within each of those folders, I have applied a consistent file
`
`naming convention. The file names in EX2231 correspond to the file names
`
`referenced in my Declaration. File names beginning with “AJM” additionally
`
`correspond to particular entries in my lab notebooks, and the file names indicate
`
`the particular lab notebook and page number corresponding to the data in the file.
`
`For example, Figure 6 in my Declaration is a PXRD pattern of the sitagliptin free
`
`base supplied from Merck. The caption to Figure 6 identifies the file name as
`
`AJM-III-25.1, and the corresponding files (AJM-III-25_1.ras, AJM-III-
`
`25_1_Theta_2-Theta.asc, AJM-III-25_1_Theta_2-Theta.raw) are in the PXRD
`
`folder of EX2231. The “III” in “AJM-III-25.1” indicates that the relevant entry is
`
`in lab notebook 3 (EX2228); the “25” indicates that the relevant entry is on page
`
`25 of the lab notebook; and the “1” indicates that it is the first piece of data
`
`generated on that page.
`
`5.
`
`In my Declaration, I described several different experimental
`
`techniques that I used to characterize the materials I generated through my salt
`
`experiments: (1) X-ray powder diffraction (PXRD or XRPD), (2) single crystal X-
`
`ray powder diffraction, (3) thermogravimetric analysis (TGA), (4) Raman
`
`spectroscopy, and (5) elemental analysis. I describe each in turn.
`
`6.
`
`X-ray diffraction: X-ray diffraction is a well-known, routine
`
`analytical technique (it is, for example, referred to in the specification of the ’708
`
`
`
`3
`
`Merck Exhibit 2269, Page 3
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040
`
`Mylan (IPR2020-00040) Ex. 1029 p. 004
`
`
`
`
`
`patent) that is used to identify crystalline forms and determine the crystal structure
`
`of a material. It can be performed on both a powder sample (X-ray powder
`
`diffraction – PXRD) of a crystalline substance or a single crystal (single crystal X-
`
`ray powder diffraction). X-ray diffraction works by irradiating a material with X-
`
`rays of a particular wavelength and then measuring the intensities and scattering
`
`angles of the X-rays that are diffracted. Because the distances between the atoms
`
`in a crystal are of a length similar to the X-ray wavelength, the presence of a
`
`crystal structure in the sample will produce an observable pattern. This pattern is
`
`unique to the crystal structure and thus can be used to identify the particular
`
`crystalline form of a material.
`
`7.
`
`I describe the protocol I used for PXRD in paragraph 142 of my
`
`declaration. I performed the various PXRD experiments detailed in EX2228 in
`
`connection with my work on this case. The data generated in connection with
`
`these experiments are in the “PXRD” folder of EX2231.
`
`8.
`
`I describe the protocol I used for single crystal X-ray diffraction in
`
`paragraph 147 of my declaration. I performed the various single crystal X-ray
`
`diffraction experiments detailed in EX2228, including the collection of single
`
`crystal data in the Rigaku XtaLAB Synergy-S X-ray diffractometer, which is in my
`
`laboratory. Additionally, I directed the collection of single crystal data on an
`
`additional piece of equipment, the Rigaku AFC10K Saturn 944+ CCD-based X-ray
`
`
`
`4
`
`Merck Exhibit 2269, Page 4
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040
`
`Mylan (IPR2020-00040) Ex. 1029 p. 005
`
`
`
`
`
`diffractometer. This latter diffractometer is not in my lab but located at a central
`
`facility at the University of Michigan. While I am familiar with how to run this
`
`diffractometer, this facility limits access to the instrument to only staff of the
`
`facility. It is standard for outside users to provide samples to the staff to run on the
`
`instrument. Thus, I prepared the sample for data collection, which involves
`
`selecting a crystal and mounting that crystal on a loop for data collection. I then
`
`passed the sample to Dr. Jeff Kampf, Director of X-ray Crystallography at the
`
`University of Michigan, who placed the sample into the X-ray beam and ran the
`
`nearly entirely automated process of data collection. I was not physically present
`
`during this data collection both due to COVID restrictions and because it is
`
`standard protocol at the University for samples to be placed in a queue and run
`
`when the diffractometer becomes available. The data generated in connection with
`
`both sets of experiments are in the “Single Crystal” folder of EX2231.
`
`9.
`
`Thermogravimetric Analysis: Thermogravimetric analysis (TGA) is
`
`a routine analytical technique (it is, for example, referred to in the specification of
`
`the ’708 patent) that measures the mass of a sample over time and/or as a function
`
`of the temperature of the sample. TGA can perform a number of functions,
`
`including showing and quantifying the loss of water over time. Thus it can be used
`
`to identify the presence of hydrates in a material. I describe the protocol I used to
`
`conduct TGA in paragraph 146 of my declaration. The TGA experiment I
`
`
`
`5
`
`Merck Exhibit 2269, Page 5
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040
`
`Mylan (IPR2020-00040) Ex. 1029 p. 006
`
`
`
`
`
`performed is detailed in EX2228, and the results are in the “TGA” folder of
`
`EX2231.
`
`10. Raman Spectroscopy: Raman spectroscopy is a routinely used
`
`analytical technique that provides detailed information about the chemical
`
`structure, phase and polymorphism, and crystallinity of a material. It is based on
`
`the interaction of light with chemical bonds within a material. Raman involves
`
`shining a high intensity light source such as a laser on a material and measuring
`
`how the molecules of that material scatter light. A Raman spectrum thus features a
`
`number of peaks that correspond to specific molecular bond vibrations. I describe
`
`the protocol I used to conduct Raman Spectroscopy in paragraph 145 of my
`
`declaration. I performed the Raman experiments detailed in EX2228 and EX2229.
`
`The Raman data I generated are in the “Raman” folder of EX2231.
`
`11. Elemental Analysis: Elemental analysis refers to a variety of
`
`techniques that are used to determine the quantity of a particular element in a
`
`material. It can be used to determine the relevant stoichiometry of compounds in a
`
`material by looking at the ratio of particular elements. I do not perform elemental
`
`analysis in my laboratory. Scientists routinely use commercial analytical services
`
`such as Galbraith Laboratories for techniques that they do not conduct in their own
`
`labs and rely upon the data generated from these services. Accordingly, I sent the
`
`samples I created to Galbraith Laboratories with instructions to measure, and to
`
`
`
`6
`
`Merck Exhibit 2269, Page 6
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040
`
`Mylan (IPR2020-00040) Ex. 1029 p. 007
`
`
`
`
`
`report back to me, the content of nitrogen and phosphorus in those samples.
`
`Galbraith Laboratories is a reputable third-party lab that specializes in a number of
`
`analytical techniques, including elemental analysis. I selected Galbraith because of
`
`its reputation and experience with analytical techniques such as elemental analysis,
`
`my previous positive experiences with Galbraith, and because its protocols for
`
`elemental analysis were appropriate for the smaller sample size of non-1:1
`
`sitagliptin phosphate salts I grew. I also note that Dr. Chyall, Teva’s expert in the
`
`Israel opposition, also selected Galbraith Laboratories to perform elemental
`
`analysis. EX2232 is a true and accurate copy of the report containing the
`
`elemental analysis results I received from Galbraith Laboratories.
`
`*
`
`*
`
`*
`
`I hereby declare that all statements made herein of my own knowledge true
`
`and that all statements made on information and belief are believed to be true; and
`
`further that these statements were made with the knowledge that willful false
`
`statements and the like so made are punishable by fine or imprisonment, or both,
`
`under Section 1001 of Title 18 of the United States Code.
`
`
`
`
`
`
`
`7
`
`Merck Exhibit 2269, Page 7
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040
`
`Mylan (IPR2020-00040) Ex. 1029 p. 008
`
`
`
`Merck Exhibit 2269, Page 8
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040
`
`Mylan (IPR2020-00040) Ex. 1029 p. 009
`
`